Pfizer’s VC arm has backed a $100 million series A raise for OTR Therapeutics, as the Chinese biotech tacks on preclinical ...

All this data builds Jefferies’ argument: the FDA change could help boost return on investment and therefore drive R&D spend.

Freenome is taking itself public via a special purpose acquisition company, also known as a SPAC deal, to help raise funds in ...

The industry’s mRNA alliance is demanding steady FDA leadership, warning that the current “unprecedented turmoil” at the ...

“SCN2A and SCN8A DEEs are devastating conditions with extremely high mortality due to the debilitating seizure burden they ...

The outside advisors analyzed the results of the RELIEVE-HF pivotal trial, which randomized 508 patients to either receive ...

Natera is looking to grow its portfolio of tools to detect the recurrence of cancer with a deal to acquire Foresight ...

Encoded Therapeutics has linked its Dravet syndrome gene therapy ETX101 to a 78% reduction in seizures, keeping the biotech ...

Almost four years after penning its first amyloidosis collaboration with Neurimmune, AstraZeneca has returned to ...

The FDA has named Tracy Beth Høeg, M.D., Ph.D., as acting director of its Center for Drug Evaluation and Research, continuing ...

The FDA has placed a hold on Denali Therapeutics’ plans to launch a phase 1 rare disease trial, citing concerns about immune ...

Paradigm Health has raised $78 million as it works to revamp the clinical research ecosystem, while also announcing a deal to ...